Venetoclax
roche,abbvie
['leukemia', 'myeloid', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'leusm']
#ash22 #leusm tiong: valdac study employed ven/ldac (600mg d1-28 and 20mg/m2 d1-10, respectively) in mrd relapse (&lt;5% blasts, n=26) cohort and oligoblastic (5-15% blasts, n=22). 42% bridged to allo, 27% had progression. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)